10-K: Kronos Bio Announces Strategic Review and Reports 2024 Financial Results

Kronos Bio discontinues istisociclib development, initiates strategic review, and reports a net loss of $86.1 million for 2024.

Summary

• Kronos Bio discontinued its istisociclib clinical trial due to emerging adverse events and initiated a strategic review to maximize stockholder value.
• The company is exploring strategic alternatives, including acquisition, merger, or asset divestiture.
• If a strategic alternative is not consummated, the board may pursue dissolution and liquidation.
• The company is exploring options for KB-9558 and KB-7898, including potential partnerships and divestiture.
• Kronos Bio reported a net loss of $86.1 million for the year ended December 31, 2024, compared to a net loss of $112.7 million for 2023.
• As of December 31, 2024, the company had $112.4 million in cash, cash equivalents, and investments.
• The company believes its existing capital resources will fund planned operating expenses and capital expenditure requirements for 12 months.
• Three corporate restructuring plans were implemented in 2024 to optimize resource allocation and contain costs, including workforce reductions.
• A transition agreement with Genentech was executed, voiding the collaboration agreement and transferring program materials to Genentech.
• The company made a one-time payment to Genentech to support the transition of activities.

Sentiment

Score: 3

Explanation: The document indicates a negative outlook due to the discontinuation of a key clinical trial, significant net losses, and the exploration of strategic alternatives that could include dissolution. However, the company has sufficient capital for the next 12 months and is actively seeking ways to maximize stockholder value.

Positives

• The company is actively exploring strategic alternatives to maximize stockholder value.
• Operating expenses decreased in 2024 compared to 2023 due to restructuring efforts.
• The company has sufficient capital to fund operations for the next 12 months.

Negatives

• The clinical trial for istisociclib (KB-0742) was discontinued due to an unfavorable risk-benefit profile.
• The company incurred a net loss of $86.1 million for 2024.
• There is no assurance that the strategic review process will result in a transaction or increased stockholder value.
• The board of directors may decide to pursue dissolution and liquidation of the company if a strategic alternative is not consummated.

Risks

• The strategic review process may not result in a transaction or enhance stockholder value.
• The company may be unable to raise additional capital when needed.
• The company has a limited operating history and faces significant challenges.
• The price of the company's common stock may be volatile and fluctuate substantially.
• The company may be unable to comply with the applicable continued listing requirements of The Nasdaq Global Select Market.

Future Outlook

The company expects its existing capital resources will fund planned operating expenses and capital expenditure requirements for 12 months. The company intends to maintain significant expense reduction strategies while it explores strategic alternatives.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary drugs. Kronos Bio operates in the segments of the pharmaceutical, biotechnology, and related markets that target transcriptional regulation in cancer.

Comparison to Industry Standards

• If KB-9558 is approved, it would compete against p300 inhibitors in early-stage clinical development, such as inobrodib (CellCentric), FT-7051 (Pathos), EP31670 (Epigenetix), TT125-802 (Tolremo), and AUR-107 (Aurigene).
• If KB-7898 is approved, it would compete against treatments for Sjögren's Syndrome in clinical development, including ianalumab (Novartis), deucravacitinib (Bristol Myers Squibb), dazodalibep (Amgen), telitacicept (RemeGen), bariicibinib (Eli Lilly), nipocalimab (Johnson & Johnson), iscalimab (Novartis), anifrolumab (AstraZeneca), efgartigimod (Argenx), and ASP45502 (Astellas).

Management Changes

Related Party Transactions

• The company incurred expenses of $0.4 million and $0.1 million for each of the years ended December 31, 2024 and December 31, 2023 for services from Two River Consulting, LLC, where Mr. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman and Mr. Joshua Kazam and Mr. David Tanen, each a director of the Company, are each partners.
• The company incurred nominal expenses for each of the years ended December 31, 2024 and December 31, 2023 for services from Bellco Capital, LLC, where Mr. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman.
• The company incurred nominal expenses under the KEOE agreement for the year ended December 31, 2024. Ms. Katherine Stultz, the Companys Director is the owner of KEOE.

Stakeholder Impact

• Shareholders face uncertainty regarding the outcome of the strategic review and potential liquidation.
• Employees have been impacted by workforce reductions.
• The discontinuation of istisociclib affects patients who may have benefited from the treatment.
• The transition agreement with Genentech impacts the future development of the collaboration programs.

Next Steps

• Continue evaluating and pursuing strategic alternatives.
• Explore options for KB-9558 and KB-7898, including potential partnerships and divestiture.
• Maintain significant expense reduction strategies.

Key Dates

Keywords

strategic review, Kronos Bio, KB-9558, KB-7898, istisociclib, Genentech, clinical trial, net loss, restructuring, biopharmaceutical